Home > News > IMAGNA project team started work on therapeutic vaccination against cat fibrosarcoma
September 20th, 2007
IMAGNA project team started work on therapeutic vaccination against cat fibrosarcoma
Abstract:
IMAGNA (immuno gene therapy with magnetic nanoparticles) has been founded by members of the Institute of Experimental Oncology Klinikum rechts der Isar (Technical University Munich), the Clinic of Small Animal Medicine of the Ludwig-Maximilians-Universität (Munich), Bayer Schering Pharma AG (Berlin), chemicell GmbH (Berlin), and PlasmidFactory GmbH & Co. KG (Bielefeld) to provide evidence for the usefulness of therapeutic tumor vaccination by the Magnetofection technology in a clinical study in cats with fibrosarcoma. This consortium is supported by a grant from the German Ministry of Education and Research (BMBF).
Source:
nanowerk.com
Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Discoveries
Breaking carbon–hydrogen bonds to make complex molecules November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Human Interest/Art
Drawing data in nanometer scale September 30th, 2022
Scientists prepare for the world’s smallest race: Nanocar Race II March 18th, 2022
Graphene nanotubes revolutionize touch screen use for prosthetic hands August 3rd, 2021
JEOL Announces 2020 Microscopy Image Grand Prize Winners January 7th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||